Share this article
Share this article
SAN FRANCISCO, Jan. 7, 2021 /PRNewswire/ Felix Biotechnology today announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for targeted phage therapy YPT-01 in the treatment of chronic
P. aeruginosa infections in cystic fibrosis. This double-blind, placebo-controlled study (
NCT 04684641) will assess the safety and efficacy of YPT-01 added to standard antimicrobial therapy in 36 patients. CYPHY will also assess the ability of YPT-01 to reduce the virulence and antibiotic-resistance of
P. aeruginosa, improving patient outcomes and re-enabling use of traditional antibiotics against multi-drug resistant strains. The lead investigator for this study, Dr. Jon Koff, Associate Professor and Director of Yale s Adult Cystic Fibrosis Program, is supported by an academic grant from the Cystic Fibrosis Foundation.